## ACAD: ACADIA Pharmaceuticals Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.0% in lower entry zone (3.0-6.0%), top quartile (87th pct) cross-sectional ranking. Short-term MRS_5 (1.1%) confirms momentum alignment. Strong momentum (+1.3% 5-day acceleration). Outperforming sector by 7.3%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($24.86)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Acadia Pharmaceuticals stock hits 52-week high at 26.65 USD By Investing.com**
- Source: Investing.com Nigeria | 20251206T052145 | Somewhat-Bullish | Relevance: 99%
- Acadia Pharmaceuticals Inc. (ACAD) has achieved a new 52-week high, with its stock price hitting $26.65 USD, indicating significant investor confidence and a 50.73% total return over the past year. Despite some analyst adjustments to price targets following a Q3 2025 earnings report, the company maintains a "GREAT" financial health score and solid revenue growth, driven by its pharmaceutical innovations. InvestingPro analysis suggests the stock is currently in overbought territory but has potential for further growth.

**2. Edgestream Partners L.P. Sells 47,964 Shares of ACADIA Pharmaceuticals Inc. $ACAD**
- Source: MarketBeat | 20251206T000938 | Somewhat-Bullish | Relevance: 98%
-  Edgestream Partners L.P. reduced its stake in ACADIA Pharmaceuticals Inc. by 30.1% in Q2, selling 47,964 shares and now holding 111,144 shares valued at $2.40 million. This comes as ACADIA Pharmaceuticals beat recent earnings and revenue estimates, with a "Moderate Buy" consensus rating among analysts and significant institutional ownership. Insiders, however, have also sold shares recently, while other large investors like American Century and Vanguard increased their positions.

**3. ACADIA Pharmaceuticals (ACAD) Receives a Buy from UBS**
- Source: The Globe and Mail | 20251207T052144 | Bullish | Relevance: 98%
-  UBS analyst Ashwani Verma has maintained a Buy rating on ACADIA Pharmaceuticals (ACAD) with a $35.00 price target, citing strong financial performance and strategic growth. The company reported significant increases in quarterly revenue and net profit. Despite negative insider sentiment from recent share sales, other analysts like Citi also issued Buy ratings, while Mizuho Securities maintained a Hold.

**4. Norges Bank Invests $31.68 Million in ACADIA Pharmaceuticals Inc. $ACAD**
- Source: MarketBeat | 20251208T110938 | Bullish | Relevance: 98%
- Norges Bank has acquired a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), purchasing 1,468,647 shares valued at approximately $31.68 million in the second quarter. This investment gives Norges Bank about 0.87% ownership of the biopharmaceutical company. The news follows ACADIA's strong Q3 earnings, where it exceeded analyst estimates with an EPS of $0.42 and revenue of $278.6 million.

**5. Acadia Pharmaceuticals (ACAD): Reassessing Valuation After Strong Q3 Earnings Beat and Higher Analyst Price Targets**
- Source: Simply Wall Street | 20251206T000938 | Bullish | Relevance: 98%
- Acadia Pharmaceuticals delivered strong Q3 earnings, surpassing forecasts and prompting analysts to raise sales outlooks for Nuplazid and Daybue. This positive momentum has fueled a significant share price rally, with the stock up over 42% year-to-date and 58% over the past year. The article suggests that while the company is currently undervalued with a fair value of $29.32, future growth potential needs to be weighed against rising R&D costs and potential price pressures.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Mizuho | $29 | $24 | +21% |
| 2025-11-17 | JP Morgan | $31 | $33 | -6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Mizuho | main | Neutral |
| 2025-11-17 | JP Morgan | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 4 ($1.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Baker Bros. Advisors: 25.4% (0.0%)
- Blackrock Inc.: 12.0% (-1.9%)
- Vanguard Group Inc: 9.0% (-0.6%)
- State Street Corpora: 4.3% (+17.4%)
- RTW Investments LP: 4.2% (-20.6%)

### Key Risks

1. Elevated short interest (8.8%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +1.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Quality metrics strong (ROE 35%, margin 25%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.45). Insider selling cluster ($1.1M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.5B |
| Beta | 0.67 |
| 52W Range | $13.40 - $27.70 |
| Short Interest | 8.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.42 |
| Forward P/E | 33.0 |
| Current P/E | 32.8 |
| YoY Growth | -0.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from 2.7% to 4.0% (+1.3% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 87th percentile. MRS_5 at 1.1% confirms short-term momentum alignment. Outperforming sector by 7.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.97% (CS: 87) | Strong |
| RSI_14 | 68.8 | Neutral |
| MACD Histogram | 0.28 | Bullish |
| vs SMA20 | 1.092x | Above |
| vs SMA50 | 1.176x | Above |
| vs SMA200 | 1.268x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $26.76
- **Stop Loss:** $24.86 (7.1% risk)
- **Target:** $29.61 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 263
- **Position Value:** $7,037.88
- **Portfolio %:** 7.04%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-25 (Est: $0.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.42 | +189.0% |
| 2025Q2 | $0.14 | $0.16 | +15.3% |
| 2025Q1 | $0.11 | $0.11 | +4.5% |
| 2024Q4 | $0.22 | $0.86 | +292.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*